Chronoscale Holdings Corp current report, 07 September 2017

Business Context and Reporting Period

This Form 8-K, dated September 7, 2017, reports on Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), a developer of exoskeleton solutions for medical, industrial, and defense applications. The filing announces the final results of a rights offering that concluded on August 31, 2017.

Key Financial Metrics

  • Gross Proceeds Raised: $34.0 million.
  • Backstop Commitment: $20.5 million from Puissance Capital Management LP.
  • Shares Issued to Rights Holders: 13,463,942 common shares (comprising 12,358,898 basic and 1,106,204 oversubscription rights).
  • Shares Issued to Backstop Investor: 20,534,898 common shares to Puissance Cross-Border Opportunities II LLC.
  • Total Shares Outstanding Post-Closing: 59,789,159 common shares.
  • Revenue, Profit, and Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.

Material Changes

The primary material change is the significant increase in share count and capitalization resulting from the fully-financed rights offering. The company successfully raised $34.0 million, with a substantial portion ($20.5 million) secured through a backstop agreement, ensuring the offering was fully subscribed.

Guidance, Outlook, and Management Commentary

CEO Thomas Looby stated the financing reflects growing investment community excitement and will provide resources to advance product adoption in rehabilitation and industrial verticals. The company plans to use net proceeds for:

  • Clinical, sales, and marketing initiatives to accelerate adoption and expand into Asia.
  • Research, development, and commercialization of a robotic exoskeleton for home use.
  • Development and commercialization of able-bodied exoskeletons for industrial use.
  • Working capital and general corporate purposes.

Corporate Governance Change: Ted Wang, Ph.D., CIO of Puissance Capital Management, is expected to join the Board of Directors.

Risks: The filing includes standard forward-looking statement disclaimers regarding risks such as the inability to obtain adequate financing, product development timelines, market acceptance, clinical study results, regulatory approvals, and competition.

Investor Verification Checklist

  • Verify the final share count of 59,789,159 outstanding shares in subsequent filings.
  • Confirm the appointment of Ted Wang to the Board of Directors.
  • Monitor the deployment of the $34.0 million gross proceeds against the stated strategic priorities (Asia expansion, home-use R&D, industrial development).
  • Review future 10-Q or 10-K filings for updated liquidity positions and cash burn rates following this capital raise.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.